Esmée P. Hoefsmit

1.0k total citations
14 papers, 355 citations indexed

About

Esmée P. Hoefsmit is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Esmée P. Hoefsmit has authored 14 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Esmée P. Hoefsmit's work include Cancer Immunotherapy and Biomarkers (10 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (4 papers). Esmée P. Hoefsmit is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (4 papers). Esmée P. Hoefsmit collaborates with scholars based in Netherlands, Australia and Germany. Esmée P. Hoefsmit's co-authors include Christian U. Blank, Mark J. Smyth, Michele W.L. Teng, Jake S. O’Donnell, Elisa A. Rozeman, John B.A.G. Haanen, Daisy I. Picavet, Yanaika S. Sabogal Piñeros, Suzanne M. Bal and Annemiek Dijkhuis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Esmée P. Hoefsmit

14 papers receiving 354 citations

Peers

Countries citing papers authored by Esmée P. Hoefsmit

Since Specialization

Citations

This map shows the geographic impact of Esmée P. Hoefsmit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esmée P. Hoefsmit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esmée P. Hoefsmit more than expected).

Fields of papers citing papers by Esmée P. Hoefsmit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esmée P. Hoefsmit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esmée P. Hoefsmit. The network helps show where Esmée P. Hoefsmit may publish in the future.

Co-authorship network of co-authors of Esmée P. Hoefsmit

This figure shows the co-authorship network connecting the top 25 collaborators of Esmée P. Hoefsmit. A scholar is included among the top collaborators of Esmée P. Hoefsmit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esmée P. Hoefsmit. Esmée P. Hoefsmit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma 2024 ·Blood ·Marie José Kersten, (unknown), Évelyne Willems, Marte C. Liefaard, Stavros Milatos, Margot J. Pont, (unknown), Eva Santermans, (unknown), Jeevan K. Shetty, Esmée P. Hoefsmit, Omotayo Fasan, Maria T. Kuipers, Sébastien Anguille, Joost S.P. Vermaat	1
2	Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma 2024 ·Cancer Immunology Immunotherapy ·Judith M. Versluis, Esmée P. Hoefsmit, (unknown), (unknown), (unknown), (unknown), Christian U. Blank	2
3	Acidity‐mediated induction of FoxP3 ⁺ regulatory T cells 2023 ·European Journal of Immunology ·Disha Rao, (unknown), Ruben Lacroix, Petros Dimitriadis, Joanna Kaplon, (unknown), (unknown), Esmée P. Hoefsmit, Kathrin Renner, Christian U. Blank, Daniel S. Peeper	17
4	Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells 2023 ·Cancer Immunology Research ·Esmée P. Hoefsmit, (unknown), Disha Rao, (unknown), Petros Dimitriadis, Cor Lieftink, Ben Morris, Elisa A. Rozeman, Irene L. M. Reijers, Ruben Lacroix, (unknown), Maarten A. Ligtenberg, Roderick L. Beijersbergen, Daniel S. Peeper, Christian U. Blank	10
5	Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections 2023 ·Cancer Immunology Immunotherapy ·Christina Schmitt, Esmée P. Hoefsmit, Thomas Fangmeier, (unknown), (unknown), Julio Vera, Judith M. Versluis, Annette Compter, Thomas Harrer, Hrvoje Mijočević, Sören Schubert, Thomas Hundsberger, Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long, Lars E. French, Christian U. Blank, Lucie Heinzerling	5
6	Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence 2023 ·Cancer Research Communications ·Esmée P. Hoefsmit, (unknown), Elisa A. Rozeman, Irene L. M. Reijers, Judith M. Versluis, Liesbeth Hoekman, Alexander C. J. van Akkooi, Georgina V. Long, Dirk Schadendorf, Reinhard Dummer, Maarten Altelaar, Christian U. Blank	9
7	RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells 2022 ·Cell Reports Medicine ·Zhengkui Zhang, Xiangjun Kong, Maarten A. Ligtenberg, (unknown), Nils L. Visser, Beaunelle de Bruijn, Kelly E. Stecker, (unknown), Thomas Kuilman, Esmée P. Hoefsmit, David W. Vredevoogd, Georgi Apriamashvili, (unknown), Emile E. Voest, Sjoerd Klarenbeek, Maarten Altelaar, Daniel S. Peeper	30
8	Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins 2022 ·Journal for ImmunoTherapy of Cancer ·Tim Fessenden, Lauren Stopfer, (unknown), (unknown), (unknown), (unknown), Irene L. M. Reijers, Esmée P. Hoefsmit, Christian U. Blank, Forest M. White, Stefani Spranger	7
9	IMPemBra, a phase 2 study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation: Three-year survival data and translational analyses. 2022 ·Journal of Clinical Oncology ·Elisa A. Rozeman, Judith M. Versluis, Esmée P. Hoefsmit, Petros Dimitriadis, Lindsay G. Grijpink-Ongering, Karolina Sikorska, Bart A. van de Wiel, (unknown), (unknown), Pia Kvistborg, Daan van den Broek, Annegien Broeks, Jan Willem de Groot, Sofie Wilgenhof, Marieke A. Vollebergh, Johannes V. van Thienen, John B.A.G. Haanen, Christian U. Blank	1
10	Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma. 2020 ·Journal of Clinical Oncology ·Elisa A. Rozeman, Irene L. M. Reijers, Esmée P. Hoefsmit, Karolina Sikorska, Oscar Krijgsman, Bart A. van de Wiel, Petros Dimitriadis, Hanna Eriksson, Maria Gonzalez, Lindsay G. Grijpink-Ongering, Ron Kerkhoven, Annegien Broeks, W. Martin C. Klop, Andrew J. Spillane, Robyn P.M. Saw, Alexander Christopher Jonathan Van Akkooi, Richard A. Scolyer, Alexander M. Menzies, Georgina V. Long, Christian U. Blank	13
11	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events 2019 ·ESMO Open ·Esmée P. Hoefsmit, Elisa A. Rozeman, John B.A.G. Haanen, Christian U. Blank	28
12	18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma 2019 ·Annals of Oncology ·Elisa A. Rozeman, Alexander M. Menzies, Oscar Krijgsman, Esmée P. Hoefsmit, Bart A. van de Wiel, Karolina Sikorska, (unknown), Hanna Eriksson, Carolien Bierman, Michel González, Kerwin F. Shannon, Annegien Broeks, Ron Kerkhoven, Andrew J. Spillane, (unknown), Alexander C. J. van Akkooi, Richard A. Scolyer, Johan Hansson, Georgina V. Long, (unknown)	14
13	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment 2019 ·Clinical Cancer Research ·Jake S. O’Donnell, Esmée P. Hoefsmit, Mark J. Smyth, Christian U. Blank, Michele W.L. Teng	136
14	Eosinophils capture viruses, a capacity that is defective in asthma 2019 ·Allergy ·Yanaika S. Sabogal Piñeros, Suzanne M. Bal, Annemiek Dijkhuis, Christof J. Majoor, Barbara Dierdorp, Tamara Dekker, Esmée P. Hoefsmit, Peter I. Bonta, Daisy I. Picavet, Nicole N. van der Wel, Leo Koenderman, Peter J. Sterk, Lara Ravanetti, René Lutter	82

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact